U.S. markets open in 2 hours 11 minutes

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
106.01+4.16 (+4.08%)
At close: 4:00PM EDT

112.17 +6.16 (5.81%)
Pre-Market: 7:00AM EDT

Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Currency in USD

Valuation Measures

Yahoo Finance Plus required to access annual data
Yahoo Finance Plus required to access monthly data
Subscribe to Yahoo Finance Plus Essential to download historical data
As of Date: 5/2/2021
Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 7

Trading Information

Stock Price History

Beta (5Y Monthly) 1.90
52-Week Change 361.36%
S&P500 52-Week Change 344.55%
52 Week High 3179.65
52 Week Low 361.96
50-Day Moving Average 3111.08
200-Day Moving Average 3127.16

Share Statistics

Avg Vol (3 month) 3423.15k
Avg Vol (10 day) 3404.96k
Shares Outstanding 567.47M
Implied Shares Outstanding 6N/A
Float 63.7M
% Held by Insiders 14.22%
% Held by Institutions 1102.11%
Shares Short (Apr 14, 2021) 45.4M
Short Ratio (Apr 14, 2021) 412.02
Short % of Float (Apr 14, 2021) 410.71%
Short % of Shares Outstanding (Apr 14, 2021) 48.07%
Shares Short (prior month Mar 14, 2021) 45.54M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:3
Last Split Date 3Jan 16, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2020
Most Recent Quarter (mrq)Mar 30, 2021


Profit Margin -60.96%
Operating Margin (ttm)-94.58%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)334.12M
Revenue Per Share (ttm)5.29
Quarterly Revenue Growth (yoy)173.70%
Gross Profit (ttm)-147.18M
EBITDA -303.55M
Net Income Avi to Common (ttm)-203.68M
Diluted EPS (ttm)-3.23
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.2B
Total Cash Per Share (mrq)17.95
Total Debt (mrq)48.23M
Total Debt/Equity (mrq)4.18
Current Ratio (mrq)N/A
Book Value Per Share (mrq)17.28

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A